Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing clinical trial literature without systematic review methodology.
PubMed 19701048 · doi:10.1097/AOG.0b013e3181b43b0e
What was done
Narrative review evaluating obstetric magnesium sulfate usage across clinical indications, comparing dosage and outcomes from three clinical trials and a recent meta-analysis regarding seizure prophylaxis, tocolysis, and fetal neuroprotection.
What was found
No specific statistical effect sizes or numerical event rates were reported in the abstract. The review reports that high doses used for tocolysis lack efficacy and cause fetal toxicity, whereas safer neuroprotection occurs at lower antenatal doses ranging between 4 g and 10.5 g before exceeding a therapeutic window.
Why it matters
It proposes a narrow therapeutic window for magnesium sulfate, helping resolve conflicting evidence by differentiating beneficial low-dose neuroprotection from harmful high-dose tocolytic regimens.
Limits
As a narrative review, it lacks formal systematic review methodology and risk of bias assessment. The abstract reports no participant counts, effect estimates, or confidence intervals.
Cited by
- supports Intravenous magnesium is used clinically to treat preeclampsia and preterm labor.